

EORTC Melanoma Group meeting

*Assisi (PG), BV Grand Hotel Assisi
27 -28 October 2022*





FACULTY

PAOLO ASCIERTO, *Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale" (Naples)*

CECILIA BECATTINI, *University of Perugia*

FRANCESCA MARIA BOSISIO, *Catholic University Leuven*

ANDREW BOTTOMLEY, *EORTC (Brussels)*

GAETAN DE SCHAETZEN, *EORTC (Brussels)*

ALEXANDER EGGERMONT, *Prinses Máxima Centrum (Utrecht)*

PAUL LORIGAN, *University of Manchester*

MARIO MANDALÀ, *University of Perugia*

DANIELA MASSI, *University of Florence*

PAUL NATHAN, *Mount Vernon Cancer Centre (Northwood)*

MAURIZIO OLIVIERO, *University of Perugia*

MARIA RESCIGNO, *Humanitas University (Milan)*

ANGELO SIDONI, *University of Perugia*

LUCA STINGENI, *University of Perugia*

VINCENZO TALESA, *University of Perugia*

SARA VALPIONE, *The Christie NHS Foundation Trust (Manchester)*

ALEXANDER VAN AKKOOI, *Melanoma Institute of Australia (Sidney)*

LOTTE VAN DER WEIJST, *EORTC (Brussels)*



PROGRAM

27

Auditorium C

- 11.50-12.00 Introduction
Luca Stingeni
- 12:00-13:00 Clinical statistics crash course - what you
always wanted to know but never dared
to ask
Sara Valpione
- 13:00-14:00 Next generation pathology: implications
for translational research and clinical trials
Francesca Maria Bosisio

14:00-17:00 EORTC Melanoma Pathology Course
Daniela Massi and Angelo Sidoni

Auditorium B

- 18:30-21:00 Steering Committee
Paul Lorigan

For the people involved in the meetings, the lunch will be served from 12.30 to 14.30.



PROGRAM

28

Auditorium A

- 08:25–08:30 SATELLITE SYMPOSIA
Welcome and introduction
Paul Lorigan and Mario Mandalà
- 08:30–09:00 Cardiovascular complications of immune
checkpoint inhibitors
Cecilia Becattini
- 09:00–09:30 Modulating the microbiome to improve
therapeutic response in cancer
Maria Rescigno



PROGRAM

28

Auditorium A

- 09:35–09:45 **OPENING CERIMONY**
Maurizio Oliviero
Rector, University of Perugia
- Vincenzo Talesa*
Head, Department of Medicine and Surgery, University of Perugia
- 09:45–09:50 **Welcome and Introduction MG Chair**
Paul Lorigan
- 09:50–09:55 **Early Career Investigators' (ECI-M) Meeting**
Welcome
Francesca Maria Bosisio and Sara Valpione
- 09:55–10:10 **Management of first recurrence after adjuvant therapy in stage III: multicenter real world data**
Georg Christian Lodde
- 10:10–10:25 **IDifferentiated Melanoma: An example of Epigenomic drift**
Daniela Mihic-Probst
- 10:25–10:40 **The TWEAK Pathway as a Discriminant between Metastasizing and Non-Metastasizing Thick Melanomas: a molecular and spatial single cell analysis analysis**
Andhari Madhavi
- 10:40–10:55 **Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/ KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma**
Oliver Kennedy



PROGRAM

28

Auditorium A

- 10:55–11:10 Questions
- 11:10–11:40 Break
- 11:40–11:55 BRAFV600 variant allele frequency predicts outcome in metastatic melanoma patients treated with BRAF and MEK inhibitors
Marco Rubatto
- 11:55–12:10 MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma – An evaluation of the multicenter prospective Skin Cancer Registry ADOREG
Sophia Kreft
- 12:10–12:20 Early Career Investigators' (ECI-M) Meeting
Closing remarks
Francesca Maria Bosisio and Sara Valpione
- 12:20–13:20 Lunch Break

13:20-13.30 PLENARY SESSION

Paul Lorigan and Mario Mandalà

13:30-14:00 Adjuvant vs neoadjuvant in early stage melanoma

Alexander Eggermont

14:00-14:30 Sequencing strategy in advanced melanoma: what the data tell us

Paolo Ascierto

EORTC melanoma group meets EORTC QoL group

14:30-15:00 QoL in melanoma: the present and the future

Andrew Bottomley and Lotte Van Der Weijst

15:00-15:40 Short communications

Effects of neoadjuvant systemic therapy on surgery time and postoperative complications of lymphnode dissections in stage III melanoma

Lisanne Zijlker

Dermoscopy as response evaluation tool for cutaneous malignant melanoma metastases treated with Talimogene Laherparepvec: a prospective feasibility study

Viola Franke



PROGRAM

28

Auditorium A

Trial design and assay validation for the phase II/III DETECTION trial: Circulating tumor DNA guided Therapy for stage IIB/C mElanoma after surgiCal resection

Rebecca Lee

External Validation of a Dutch Predictive Nomogram for Complete Response to T-VEC in an Independent American Patient Cohort

Viola Franke

15:40-17:40 New study Proposals

Paul Nathan

17:40-17:55 HQ Report

Gaetan De Schetzen

17:55-18:15 EORTC 2139 (Columbus AD) and MINITUB

Alexander van Akkooi

18:15-18:20 Meeting Closure

Paul Lorigan and Mario Mandalà

20:00

Gala Dinner



INFORMAZIONI GENERALI

ECM

Il Convegno è stato accreditato per Medico Chirurgo con Specializzazione in Chirurgia Generale, Dermatologia e Venereologia, Oncologia, Patologia Clinica, Radioterapia.

- Biologo

I crediti assegnati all'evento sono 6. Il Convegno è a numero chiuso e i posti disponibili ai fini dell'ottenimento dei crediti ECM sono 100 (rif. ID 916-361180).

E' accreditata con ECM solo la giornata del 28 ottobre.

OBIETTIVO FORMATIVO

Linee guida - protocolli - procedure.

QUESTIONARIO DI VERIFICA ECM ED INFORMAZIONI VARIE

La documentazione ECM sarà on-line sul sito www.consultaumbria.com

Si ricorda che da comunicazione Age.Na.S del 15 dicembre 2016 il questionario di verifica on-line consente di effettuare una sola e non ripetibile compilazione del test. L'assegnazione dei crediti formativi rimane, comunque, subordinata a:

- presenza in sala per il 90% della durata dell'evento;
- risposta corretta al 75% dei quesiti del questionario di apprendimento

ISCRIZIONE

L'iscrizione al Convegno è gratuita e potrà essere effettuata collegandosi al sito www.consultaumbria.com

SEDE DEL CONVEGNO

BV Grand Hotel Assisi

Via G. Renzi, 2 - Assisi (PG)

RESPONSABILE SCIENTIFICO

Prof. Mario Mandalà

Email: mario.mandala@unipg.it

SEGRETERIA ORGANIZZATIVA E PROVIDER ECM

Consulta Umbria Srl

Via R. Gallenga, 2 - 06127 Perugia

Tel. 075 5000066 - email: info@consultaumbria.com





Con la sponsorizzazione non condizionante di:

 Bristol Myers Squibb

IMMUNOCORE



Una Divisione Pierre Fabre Pharmaz

